The goal of this clinical trial is to learn about Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer after Laparoscopic Gastrectomy with D2 Lymphadenectomy. The main question it aims to answer is: whether HIPEC can effectively improving the 5-year overall survival rate and decrease the peritoneal metastases rate of patients with advanced gastric cancer underwent Laparoscopic Gastrectomy with D2 Lymphadenectomy. Participants will be divided into two groups, Experimental group received laparoscopic (robotic) D2 surgery plus HIPEC2 times plus systemic chemotherapy 6\~8 cycles; and Control group received laparoscopic (robotic) D2 surgery plus systemic chemotherapy 6\~8 cycles.
None
None
The Affiliated Hospital of Qingdao University
Lead sponsor
Shandong Cancer Hospital and Institute
Collaborator
Chinese PLA General Hospital
Collaborator
Zibo Central Hospital
Collaborator
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Collaborator
Jinan Central Hospital
Collaborator
Qilu Hospital of Shandong University
Collaborator
Yantai Yuhuangding Hospital
Collaborator
Nanfang Hospital, Southern Medical University
Collaborator
Shandong First Medical University
Collaborator
The First Affiliated Hospital of Nanchang University
Collaborator
Hebei Medical University Fourth Hospital
Collaborator
Peking University Cancer Hospital & Institute
Collaborator
Peking University People's Hospital
Collaborator
Tianjin Cancer Hospital
Collaborator
First Affiliated Hospital Xi'an Jiaotong University
Collaborator
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborator
Zhongnan Hospital
Collaborator
Brigham and Women's Hospital
Collaborator
Second Xiangya Hospital of Central South University
Collaborator
Weihai Municipal Hospital
Collaborator
Mountain University Cancer Hospital
Collaborator
Ruijin Hospital
Collaborator